Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Invesco Ltd.

Key Points

• Invesco Ltd. reduced its stake in Teva Pharmaceutical Industries by 22.7%, selling 1,377,277 shares, bringing its total ownership down to approximately 4.7 million shares valued at about $72 million.
• Analysts have shown increasing optimism for Teva, with several firms raising their ratings and target prices, including a target of $25.00 from Truist Financial and a new average price target of $24.71.
• Teva reported earnings of $0.66 per share for the latest quarter, surpassing estimates and reflecting a year-over-year revenue increase of 0.3%, although it fell short of analysts' expectations by about $160 million.

Invesco Ltd. lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 22.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,687,252 shares of the company's stock after selling 1,377,277 shares during the period. Invesco Ltd. owned 0.41% of Teva Pharmaceutical Industries worth $72,043,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. increased its position in Teva Pharmaceutical Industries by 5.7% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after acquiring an additional 134,705 shares during the period. Financial Sense Advisors Inc. boosted its holdings in Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after purchasing an additional 157,421 shares in the last quarter. King Wealth Management Group boosted its holdings in Teva Pharmaceutical Industries by 1,106.9% in the 1st quarter. King Wealth Management Group now owns 175,000 shares of the company's stock valued at $2,690,000 after purchasing an additional 160,500 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock valued at $1,037,000 after purchasing an additional 60,016 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 1.2% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after purchasing an additional 300,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Matthew Shields sold 6,206 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,001 shares of company stock worth $996,958 in the last ninety days. Insiders own 0.49% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.5050 on Tuesday, reaching $17.5550. The company had a trading volume of 12,485,740 shares, compared to its average volume of 12,168,104. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The company's fifty day moving average is $16.69 and its 200 day moving average is $16.24. The company has a market cap of $20.13 billion, a P/E ratio of -109.72, a PEG ratio of 1.06 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the prior year, the company earned $0.61 EPS. Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.